Funder
National Cancer Institute
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health
Reference80 articles.
1. Dietrich, J., Monje, M., Wefel, J., Meyers, C., & Pappas, C. (2008). Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. The Oncologist, 13, 1285–1295.
2. Lee, D. W., et al. (2019). ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biology of Blood and Marrow Transplantation, 25, 625–638.
3. Taraseviciute, A., et al. (2018). Neurotoxicity associated with CD19-targeted CAR-T cell therapies. CNS Drugs. https://doi.org/10.1007/s40263-018-0582-9
4. Buchbinder, D., et al. (2018). 2018 Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. Bone Marrow Transplantation, 535(53), 535–555.
5. Food, U. S., Administration, D., & Others. (2009). Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. Federal Register, 74, 65132–65133.